GlucoTrack
GCTK
3 hedge funds and large institutions have $594K invested in GlucoTrack in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.
50% more funds holding
Funds holding: 2 → 3 (+1)
0% more ownership
Funds ownership: 0% → 0% (0%)
20% less capital invested
Capital invested by funds: $743K → $594K (-$149K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boston Financial Management
Boston,
Massachusetts
|
+$27K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$27K |
GCTK Hedge Fund Activity: Q3 2023 in Review
3 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in GlucoTrack (GCTK) for Q3 2023, worth a combined $594K — down 20% from $743K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new GCTK positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Boston Financial Management, opening a new position worth an estimated $27K. The largest seller was Sabby Management, cutting an estimated $27K.
- 3 institutional investors held GlucoTrack (GCTK) as of Q3 2023, up from 2 in Q2 2023.
- Funds reported $594K of GlucoTrack stock for Q3 2023, down 20% quarter-over-quarter.
- 1 fund opened new GlucoTrack positions in Q3 2023 and 0 closed out, a net change of +1 holder.
- The largest GlucoTrack buyer in Q3 2023 was Boston Financial Management, an estimated $27K added.
- The largest GlucoTrack seller in Q3 2023 was Sabby Management, an estimated $27K sold.
Based on aggregated 13F filings for Q3 2023.